Navigation Links
Oxford licenses anti-inflammatory peptides to San Francisco Bay Area start-up
Date:7/31/2014

, MD said: "All the biologic drugs that we currently use for treating conditions such as psoriasis work by dampening down inflammation all over the body, not just in the skin where the disease occurs. As a result they all have general immunosuppressive side-effects such as increases in number and severity of infections."

The peptides are derived from the plasma protein chemerin and work by reducing the production of inflammatory signaling proteins called cytokines which play a central role in the body's response to infection and injury. They are also implicated in the excessive immune responses underlying inflammatory diseases. The peptides inhibit activated antigen presenting cells by reducing the production of inflammatory cytokines including IL-12/23, TNFalpha, RANTES, IL-6 and IL-1beta.

Isis has granted Rogne an exclusive, world-wide licence to the associated patents.

The initial work in Professor Greaves' lab investigating inflammation was funded by the British Heart Foundation in the context of possible novel anti-inflammatory treatments for cardiovascular disease.  Professor Jeremy Pearson, Associate Medical Director at the Foundation, said: "We are delighted that the research we funded has now led to a potential new anti-inflammatory treatment for psoriasis."

Media enquiries:
Renate Krelle
Isis Innovation Ltd
renate.krelle@isis.ox.ac.uk
T: +44(0)1865280867

Lena Wu
Rogne Bioscience, Inc.
info@rognebioscience.com

About Isis Innovation

Isis Innovation is the research and technology commercialisation company of the University of Oxford. We provide access to technology from Oxford researchers through intellectual property licensing, spin-out company formation and material sales, and to academi
'/>"/>

SOURCE Rogne Bioscience, Inc.; Isis Innovation Ltd
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oxford BioTherapeutics Appoints C. Glenn Begley as a Senior Clinical Advisor and Non-executive Director
2. Oxford Finance Provides $15 Million Senior Secured Credit Facility to Private Equity Backed Healthcare Services Company
3. Oxford Finance and Silicon Valley Bank Provide $15 Million Senior Credit Facility to NanoString Technologies
4. Oxford Finance Completes $271.4 Million Securitization Transaction
5. Oxford University Hospitals NHS Trust and the Bodleian Libraries Select ClinicalKey
6. Oxford Performance Materials and Biomet Microfixation Join Forces
7. Oxford BioTherapeutics and Boehringer Ingelheim Enter Collaboration to Discover Novel Antibody Targets in Cancer
8. Oxford BioMedica Announces Update from ARVO 2013
9. Oxford University Press to publish BioScience journal starting in 2014
10. Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors
11. HistoRx Licenses Melanoma Assay from Yale University
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... (PRWEB) October 24, 2014 This ... PHA, PBS, Starch Based Plastics, Regenerated Cellulose, PCL), ... Global Trends and Forecasts to 2019”, defines and ... analysis and forecast of its global volume and ... 54 Figures spread through 178 Slides and in-depth ...
(Date:10/25/2014)... SonaCare Medical, LLC, leader in ... announced that its Board of Directors has appointed ... President and member of the Board effective immediately. ... expanded responsibilities within the company, including further developing ... commercialization, manufacturing and finance. , Dr. Carol ...
(Date:10/25/2014)... 2014 Berkshire Corporation, the world ... announce the release of the ValuSeal® IonX™ cleanroom ... contamination containment in critical processing applications. , Recommended ... cleanroom environments, ValuSeal® IonX™ is a laser sealed ... that continues Berkshire’s innovative focus on meeting new ...
(Date:10/25/2014)... YORK , Oct. 24, 2014 ... Inc. (ACCP), a biopharmaceutical company advancing patient care ... 1-for-50 reverse split of its common stock effective ... 24, 2014. PlasmaTech,s common stock will trade on ... and temporary ticker symbol "ACCPD". After 20 days, ...
Breaking Biology Technology:Biodegradable Plastics Market Projected to $3,476.87 Million by 2019 - Report by MarketsandMarkets 2Biodegradable Plastics Market Projected to $3,476.87 Million by 2019 - Report by MarketsandMarkets 3Biodegradable Plastics Market Projected to $3,476.87 Million by 2019 - Report by MarketsandMarkets 4SonaCare Medical Board of Directors Appoints Dr. Mark Carol as CEO and President 2SonaCare Medical Board of Directors Appoints Dr. Mark Carol as CEO and President 3Ions Are Bygones, Berkshire Announces the Release of New Innovative Cleanroom Wipers 2PlasmaTech Biopharmaceuticals, Inc. Announces Reverse Stock Split, Ticker Change and Launches New Corporate Website 2
... , , , , Multiporator / Electroporator 2510 , , , , ... Transformation Protocol , Protocol No. 4308 915.509 12/2001 , ... , , , , ... , Cell type , Bacteria, gram positive, ...
... , , , , , , , , ... Protocol No. 4308 915.508 12/2001 , , , , , ... , Microorganism , Brucella abortus, ... Bacteria, gram negative, , , ...
... , , , , , , Multiporator / Electroporator 2510 , , ... , Transformation Protocol , Protocol No. 4308 ... , , , , , , ... , , Cell type , ...
Cached Biology Technology:Clostridium botulinum 2Brucella abortus 2Agrobacterium tumefaciens 2
(Date:10/25/2014)... 2014 Research and Markets  has announced ... 2014-2018" report to their offering. ... on the basis of their physical or behavioral patterns. ... traits such as fingerprints, face recognition, DNA, palm print, ... as keystroke patterns and speech pattern/voice recognition. ...
(Date:10/22/2014)... 21, 2014 Aware, Inc. (NASDAQ: AWRE ... reported financial results for its third quarter ended September 30, ... was $6.0 million, an increase of 40% compared to $4.3 ... the third quarter of 2014 was $4.1 million compared to ... income in the current three month period was primarily due ...
(Date:10/18/2014)... sample of patients with undiagnosed, suspected genetic conditions, a ... a higher molecular diagnostic yield than traditional molecular diagnostic ... . The study is being released to coincide with ... Exome sequencing, which sequences the protein­coding region of the ... present in a cell or organism), has been rapidly ...
Breaking Biology News(10 mins):Biometrics Market in Europe 2014-2018: Key Vendors are 3M Cogent, Cognitec, NEC and Safran 2Biometrics Market in Europe 2014-2018: Key Vendors are 3M Cogent, Cognitec, NEC and Safran 3Aware, Inc. Reports Third Quarter 2014 Financial Results 2Aware, Inc. Reports Third Quarter 2014 Financial Results 3Aware, Inc. Reports Third Quarter 2014 Financial Results 4Aware, Inc. Reports Third Quarter 2014 Financial Results 5Aware, Inc. Reports Third Quarter 2014 Financial Results 6Aware, Inc. Reports Third Quarter 2014 Financial Results 7Study examines type of exome sequencing and molecular diagnostic yield 2Study examines type of exome sequencing and molecular diagnostic yield 3
... MADISON Failing to see the forest for ... declining health of Wisconsin,s forest ecosystems. Even areas ... as forests are increasingly fragmented by roads and development, ... fields, housing tracts, and strip malls, say University of ...
... rings are acclaimed in representing natural climate archives. ... growth of these annual rings depend mainly on temperature ... slight seasonal variations, the correlation is not so ... for Geosciences and their colleagues of the Australian National ...
... Versartis, Inc., an emerging company developing novel biologics ... presented data for its long-acting product candidates, VRS-317 (hGH-rPEG) ... (IL-1ra-rPEG) for treatment of type 1 and type 2 ... DC. Versartis, through a unique licensing agreement with Amunix, ...
Cached Biology News:Isolated forest patches lose species, diversity 2Isolated forest patches lose species, diversity 3Australia's climate: Drought and flooding in annual rings of tropical trees 2Versartis presents positive preclinical data on 2 product candidates at ENDO 09 2
Acetate Plate Sealers 100/Box...
QCPN...
... The new MALDI O-TOF creates a new ... an orthogonal platform that has been licensed ... University of Manitoba. , As the first ... design and collisional cooling, the prOTOF 2000 ...
Rat Aortic Endothelial Cells (RAOEC) (>500,000 cells)...
Biology Products: